Immunovant

IMVT Rare disease Lead: Phase 3 5 Biotech Distilled articles ↓

Most recent annual filing: 2026-05-20

Catalyst timeline

IMVT-1402 topline2026IMVT-1402 topline, 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

imeroprubart

IMVT-1402

Protein Target: FcRn

Graves' Disease Phase 2 subcutaneous HanAll NCT06727604
Rheumatoid Arthritis Phase 2 subcutaneous HanAll NCT06754462
Myasthenia Gravis Phase 3 subcutaneous HanAll NCT07039916
Chronic Inflammatory Demyelinating Polyneuropathy Phase 2 subcutaneous HanAll NCT07032662
Sjögren's Disease Phase 2 subcutaneous HanAll NCT06979531
Cutaneous Lupus Erythematosus Phase 2 subcutaneous HanAll NCT06980805

Discontinued (1)

batoclimab — Thyroid Eye Disease · Company discontinued further development of batoclimab across all indications to focus fully on IMVT-1402

Biotech Distilled coverage (5)

2026-08-07 UPDATE: Immunovant (IMVT) - The Quarter Where the Burn Got Real
2026-05-20 UPDATE: Immunovant (IMVT) - The Bio-Better Bet Cashes Its First Check 🔒 Paid
2026-04-04 UPDATE: Immunovant (IMVT) - The Bato Swan Song and the Pivot to Purity 🔒 Paid
2026-02-07 UPDATE: Immunovant (IMVT) - Quarterly Update 🔒 Paid
2026-02-02 Immunovant (IMVT): Scientific Deep Dive for IMVT-1402 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.